Non invasive testing is the buzzword in promoting breast tissue examinations. It really makes sense, and the concept is so simple, it soothes concern for all involved. As technology increases, taboo subjects find logical cures. Breast cancer affects 200,000 U.S. women per year, but that really doesn’t scratch the surface for the other 800,000 who had unending weeks of waiting and concern using today’s methods. Seventy to 80 percent of biopsies turn out to have been negative or unnecessary. One company has a noble approach, and an experienced team with a passionate marketplace.
Currently women get tested for breast cancer by attending a clinic with many invasive techniques that makes the entire experience the equivalence of an alien probe. That doesn’t even begin the emotional trauma that follows regarding decisions about biopsies that liken surgery to archaic methods used on the civil war battlefields. Empathy is due to anyone who has had a loved one that endured this violation of their privacy in such a sensitive area. A solution is needed not just for biopsy determination, but to test all women on a regular basis so they can have happy and emotionally healthy lives when evaluating their overall wellness. It is actually abominable that more is not being done in this space. It isn’t even logical to talk about normal things investors would discuss, such as size of the market or the revenue model. In the end, an educated option for women is needed and this company’s product is worth researching.
Imaging Diagnostic Systems Inc (OTCBB: IMDS) is a medical technology company engaged primarily in the research, development and marketing of its non-invasive breast imaging system. The company had made major strides in the detection of breast abnormalities, but in 2001, inventor and co-founder, Richard Grable died. He clearly passed on too early while his work was in the prime of its career. Adhering to a simple concept to examine potential cancerous tumors in women, he concluded (logically) and began development of a non invasive testing system for women that through the use of laser technology, could recognize (larger than normal) amounts of blood flow in the breast. This identified an area of concern because all cancerous tumors need higher levels of blood flow to grow. This simple identifier may prove more effective than all other methods and should remove much of the trauma of the breast exam for women of all ages. So says Tim Hansen, CEO of IMDS.
He continues, “There are different types of imaging: X-rays, MRI, CT scans, nuclear medicine, ultrasound and now light beams. Light beams are perfect for soft tissue imaging. This molecular level exam lends itself to non-bone imaging. Many of the other imaging methods work for non-breast studies, but clearly for soft tissue related testing; we feel Laser Mammography is the most promising option to differentiate cancer from non cancer.”
Quoting some recent statistics Hansen adds, “Seventy percent of biopsies are negative, unnecessary and traumatic. It normally is a false alarm and unneeded trauma to the patient. Our technology may solve some of these problems.”
Mammography is a serious business, and to ensure the quality of results, even has its own act of Congress, the MQSRA or the Mammography Quality Standards Reauthorization Act of 1993. IMDS is also a leadership company. They have 19 patents, 7000 clinical cases under their belt, testing equipment in many European medical centers, not to mention multiple sales in the Middle East where women prefer non invasive techniques like laser imaging because of culture considerations.
IMDS has had some trauma of its own in restructuring since the death of its founder. The effort continues through restructuring of the management team, board of directors, and sales strategy. But with angel investors making funding for the company a non-issue, IMDS needs to focus on shipping its CTLM product to countries where approvals have been given. This company, if any, deserves success for its noble cause in honor of its founder and the needs of women across the world that should have reliable non invasive testing for a proper piece of mind.
